ストックスクリーナーアプリを入手
7.72
2.39%
0.18
アフターアワーズ：
7.72
前日終値:
$7.54
開ける：
$7.53
24時間の取引高:
102.14K
Relative Volume:
0.55
時価総額：
$160.58M
収益：
-
当期純損益:
$-117.17M
株価収益率:
-5.8045
EPS:
-1.33
ネットキャッシュフロー:
$-91.71M
1週間 パフォーマンス:
-0.52%
1か月 パフォーマンス:
+2.52%
6か月 パフォーマンス:
-25.98%
1年 パフォーマンス:
-17.10%
1日の値動き範囲:
$7.26
$7.7672
1週間の範囲:
$7.17
$8.07
52週間の値動き範囲:
$6.38
$29.70
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
名前
Adverum Biotechnologies Inc
セクター
電話
(650) 649-1004
住所
100 CARDINAL WAY, REDWOOD CITY, CA
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-07 | アップグレード | Truist | Hold → Buy |
| 2021-07-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | ダウングレード | Truist | Buy → Hold |
| 2020-12-16 | 開始されました | UBS | Neutral |
| 2020-11-12 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-05-05 | アップグレード | SunTrust | Hold → Buy |
| 2020-04-28 | 開始されました | Goldman | Buy |
| 2020-03-16 | 開始されました | SVB Leerink | Outperform |
| 2020-02-10 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | 繰り返されました | Chardan Capital Markets | Neutral |
| 2019-09-13 | 繰り返されました | Chardan Capital Markets | Neutral |
| 2019-06-14 | 再開されました | Raymond James | Mkt Perform |
| 2018-11-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | ダウングレード | SunTrust | Buy → Hold |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-30 | 開始されました | SunTrust | Buy |
| 2018-02-15 | 再開されました | Piper Jaffray | Overweight |
| 2017-10-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Adverum Biotechnologies Inc (ADVM) 最新ニュース
Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of Canada - MarketBeat
Adverum Biotechnologies Advances in Gene Therapy Development - TipRanks
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Adverum Biotechnologies: Q3 Earnings Snapshot - San Antonio Express-News
Adverum Biotechnologies Reports Third Quarter 2024 - GlobeNewswire
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate - The Bakersfield Californian
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - StockTitan
Assenagon Asset Management S.A. Has $164,000 Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Update - MarketBeat
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adverum Biotechnologies names new chief commercial officer - Investing.com
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief - GlobeNewswire
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - StockTitan
Dimensional Fund Advisors LP Buys 196,884 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Squarepoint Ops LLC Raises Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Purchased by Marshall Wace LLP - MarketBeat
ADVM Stock Sees Surge of Approximately 3.49% in Last Five Days - Knox Daily
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance
Bet on 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance
Logos Global Management LP Sells 1,083,333 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Wall Street SWOT: Adverum Biotechnologies stock faces pivotal year amid trials - Investing.com
Mizuho Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendation - MSN
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $28.17 Average Target Price from Analysts - MarketBeat
(ADVM) Trading Advice - Stock Traders Daily
Logos Global Management LP Cuts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Share Price Passes Below Two Hundred Day Moving Average of $9.52 - MarketBeat
(ADVM) Investment Analysis - Stock Traders Daily
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - ForexTV.com
Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High? - Yahoo Finance
Adverum Biotechnologies Inc (ADVM) rating initates by Oppenheimer - Knox Daily
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Increase in Short Interest - Defense World
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Growth in Short Interest - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Share Price Crosses Above Fifty Day Moving Average of $7.31 - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Shares Pass Above 50-Day Moving Average of $7.31 - MarketBeat
Adverum Biotechnologies, Inc. Appoints Eric G. Carter to its Board of Directors - Marketscreener.com
The Potential Rise in the Price of Adverum Biotechnologies Inc (ADVM) following insiders activity - Knox Daily
Assenagon Asset Management S.A. Boosts Stock Position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat
Mizuho cuts Adverum Biotechnologies target to $20 from $22 By Investing.com - Investing.com Canada
(ADVM) Long Term Investment Analysis - Stock Traders Daily
FY2024 EPS Estimates for Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Boosted by Chardan Capital - Defense World
Adverum Biotechnologies, Inc. Forecasted to Earn FY2024 Earnings of ($4.07) Per Share (NASDAQ:ADVM) - MarketBeat
Brokers Offer Predictions for Adverum Biotechnologies, Inc.’s Q3 2024 Earnings (NASDAQ:ADVM) - Defense World
Brokers Issue Forecasts for Adverum Biotechnologies, Inc.'s FY2025 Earnings (NASDAQ:ADVM) - MarketBeat
Adverum Biotechnologies, Inc. to Post FY2025 Earnings of ($4.31) Per Share, Chardan Capital Forecasts (NASDAQ:ADVM) - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $40.00 by Analysts at Truist Financial - Defense World
Adverum Biotechnologies (NASDAQ:ADVM) Upgraded to “Hold” at StockNews.com - Defense World
Adverum Biotechnologies Inc (ADVM) 財務データ
収益
当期純利益
現金流量
EPS
Adverum Biotechnologies Inc (ADVM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% Owner |
Jul 17 '24 |
Buy |
7.75 |
135,546 |
1,049,926 |
2,101,546 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
9.11 |
80,718 |
735,736 |
2,182,264 |
| Scopa James Paul | Director |
Feb 07 '24 |
Buy |
1.35 |
100,000 |
135,000 |
100,000 |
| Lupher, Jr. Mark L. | Director |
Feb 07 '24 |
Buy |
1.35 |
130,000 |
175,500 |
130,000 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):